• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MediWound touts Phase II study

January 31, 2017 By Sarah Faulkner

MediWound touts Phase II studyMediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure.

The randomized phase II trial enrolled 73 patients with a variety of chronic and hard-to-heal wounds including diabetic foot ulcers and venous leg ulcers. Patients received either EscharEx or a hydrogel placebo.

The primary endpoint of the trial was incidence of complete debridement, non-viable tissue removal, at the end of 10 days of treatment. Secondary endpoints included time to debridement, wound healing and other efficacy and safety measures, according to MediWound.

The study met its primary endpoints, the company wrote in a regulatory filing. Patients treated with EscharEx had a higher incidence of complete debridement compared with patients treated with the hydrogel placebo and achieved debridement faster than their counterparts in the control group.

“We completed the study follow-up period and are happy to reaffirm the previously reported positive results. These final results reinforce our belief that EscharEx has the potential to become a first-in-class topical debridement treatment for chronic wounds,” MediWound CEO Gal Cohen said in prepared remarks. “As reported previously, following the successful completion of this first cohort of the Phase 2 study, we initiated a second cohort of 32 patients to demonstrate safety over extended periods of application to further support product application periods of 24 to 48 hours, which we believe will enhance convenience and compliance. Patients with DFUs and VLUs are randomized to either EscharEx or gel vehicle treatment at a ratio of 2:1. We expect to complete the second cohort of the Phase II study and to report top-line data in mid-2017.”

MDWD shares were trading at $5.70 apiece in mid-afternoon activity, up 9.6%.

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wound Care Tagged With: MediWound

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Reader Interactions

Comments

  1. Enemaku Sunday says

    August 3, 2018 at 1:57 am

    I am diabetic with sores on my leg after reading about this bandage I would want to get it but I live in Nigeria so help send it on order

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS